Å·ÃÀAV

Å·ÃÀAV The Å·ÃÀAV is the world's leading chemistry community, advancing excellence in the chemical sciences. With over 48,000 members and a knowledge business that spans the globe, we are the UK's professional body for chemical scientists; a not-for-profit organisation with 170 years of history and an international vision for the future. We promote, support and celebrate chemistry. We work to shape the future of the chemical sciences - for the benefit of science and humanity. Daiichi Sankyo India Pharma Pvt. Ltd Daiichi Sankyo India Pharma Pvt. Ltd. (DSIN) was established in 2007 as a wholly owned subsidiary of Daiichi Sankyo Co. Ltd, a pharmaceutical company with more than 100 years' history. The Daiichi Sankyo Life Science Research Centre in India (RCI) is the research-based drug discovery arm of DSIN. The mission of RCI is to create first-in-class and best-in-class drugs which meet medical needs throughout the world. With a strength of more than 150 scientists, RCI focuses on small molecule drug discovery research in the areas of infectious and autoimmune diseases. RCI is equipped with state-of-the-art laboratories for the design, synthesis and evaluation of new chemical entities using in vitro and in vivo experimental set-ups to measure biological activity and drug-like characteristics. To achieve its mission, DSIN has identified certain values and commitments as the basis its attitude of cooperation and proper value judgment. In alignment with its values - which include innovation, integrity and accountability - RCI is open to collaborations with academic institutes, scientific societies and government organizations. Such collaborations contribute not only towards the identification of novel biological pathways and novel chemical scaffolds, but also provide several opportunities for mutual learning and knowledge sharing. Ranbaxy Ranbaxy Laboratories Limited is a research based global pharmaceutical company headquartered in India. A member of Daiichi Sankyo Group, Ranbaxy develops, produces and markets high quality, affordable generic medicines in over a 125 countries. Ranbaxy and Daiichi Sankyo are successfully working together in advancing a unique Hybrid Business Model that comprehensively addresses the requirements of Doctors and Patients, while improving the availability and accessibility to high quality affordable medication.